EOLS
$3.74
Evolus
($.26)
(6.50%)
EOLS
Earnings Whisper ®
N/A
4th Quarter December 2020
Consensus:  ($0.40)
Revenue:  $19.91 Mil
Thursday
Jan 28
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when EOLS reports earnings?
Beat
Meet
Miss

Where is EOLS's stock price going from here?
Up
Flat
Down
Stock chart of EOLS
Analysts
Summary of analysts' recommendations for EOLS
Score
Grade
Pivots
Resistance
$5.02
$4.61
$4.31

$3.90

Support
$3.60
$3.19
$2.89
Tweet
Growth
Description
Evolus, Inc. is a medical aesthetics company. It focuses on providing physicians and patients in aesthetic procedures and treatments. The company focuses on the self-pay aesthetic market and its lead product candidate, DWP-450, is an injectable 900 kDa purified botulinum toxin type A complex. Evolus, Inc. is based in Irvine, California.